BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, Geissler M, Makowiec F, Obermaier R, Hopt UT, Blum HE. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology. 2008;48:1821-1833. [PMID: 19003875 DOI: 10.1002/hep.22535] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, Blum HE, Neumann-Haefelin C, Thimme R. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2014;59:1415-1426. [PMID: 24002931 DOI: 10.1002/hep.26731] [Cited by in Crossref: 177] [Cited by in F6Publishing: 181] [Article Influence: 22.1] [Reference Citation Analysis]
2 Fatourou EM, Koskinas JS. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Review of Anticancer Therapy 2014;9:1499-510. [DOI: 10.1586/era.09.103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
3 Behboudi S, Alisa A, Boswell S, Anastassiou J, Pathan AA, Williams R. Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease. Br J Cancer 2010;102:748-53. [PMID: 20087354 DOI: 10.1038/sj.bjc.6605526] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
4 Woller N, Engelskircher SA, Wirth T, Wedemeyer H. Prospects and Challenges for T Cell-Based Therapies of HCC. Cells 2021;10:1651. [PMID: 34209393 DOI: 10.3390/cells10071651] [Reference Citation Analysis]
5 Schinazi RF, Bassit L, Gavegnano C. HCV drug discovery aimed at viral eradication. J Viral Hepat. 2010;17:77-90. [PMID: 20040045 DOI: 10.1111/j.1365-2893.2009.01246.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
6 Busato D, Mossenta M, Baboci L, Di Cintio F, Toffoli G, Dal Bo M. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev Clin Pharmacol 2019;12:453-70. [PMID: 30907177 DOI: 10.1080/17512433.2019.1598859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
7 Zheng J, Sun B, Liu D, Yan L, Wang Y. Treatment with transcatheter arterial chemoembolization induces an increase of the L-selectin(low) CXCR3+ CD8+ T cell subset in patients with hepatocellular carcinoma. Onco Targets Ther 2012;5:103-9. [PMID: 22719212 DOI: 10.2147/OTT.S31816] [Reference Citation Analysis]
8 Shuai Z, Leung MW, He X, Zhang W, Yang G, Leung PS, Eric Gershwin M. Adaptive immunity in the liver. Cell Mol Immunol 2016;13:354-68. [PMID: 26996069 DOI: 10.1038/cmi.2016.4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
9 Witkowski M, Spangenberg HC, Neumann-Haefelin C, Büttner N, Breous E, Kersting N, Drognitz O, Hopt UT, Blum HE, Semmo N, Thimme R. Lack of ex vivo peripheral and intrahepatic α-fetoprotein-specific CD4+ responses in hepatocellular carcinoma. Int J Cancer 2011;129:2171-82. [PMID: 21170957 DOI: 10.1002/ijc.25866] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
10 Mizukoshi E, Kaneko S. Immune cell therapy for hepatocellular carcinoma. J Hematol Oncol 2019;12:52. [PMID: 31142330 DOI: 10.1186/s13045-019-0742-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
11 Behboudi S, Boswell S, Williams R. Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma. Liver Int. 2010;30:521-526. [PMID: 20040052 DOI: 10.1111/j.1478-3231.2009.02194.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
12 Tauber C, Schultheiss M, Luca R, Buettner N, Llewellyn-Lacey S, Emmerich F, Zehe S, Price DA, Neumann-Haefelin C, Schmitt-Graeff A, Hofmann M, Thimme R. Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma. Oncotarget. 2019;10:5194-5206. [PMID: 31497249 DOI: 10.18632/oncotarget.27146] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
13 Escors D. Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci. 2014;2014:pii 734515. [PMID: 24634791 DOI: 10.1155/2014/734515] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
14 Zeng P, Shen D, Zeng CH, Chang XF, Teng GJ. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Curr Oncol Rep 2020;22:76. [PMID: 32596779 DOI: 10.1007/s11912-020-00943-6] [Reference Citation Analysis]
15 Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S, Toro A, Di Carlo I, Malaguarnera G, Bertino N. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int. 2015;2015:731469. [PMID: 25893197 DOI: 10.1155/2015/731469] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
16 Flecken T, Spangenberg HC, Thimme R. Immunobiology of hepatocellular carcinoma. Langenbecks Arch Surg. 2012;397:673-680. [PMID: 21479622 DOI: 10.1007/s00423-011-0783-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
17 Zhang BH, Wang XH, Yue HY, Ling CQ. A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:821-827. [PMID: 19916022 DOI: 10.1007/s00432-009-0722-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
18 Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC, Lim SG, Bertoletti A. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2009;137:682-690. [PMID: 19394336 DOI: 10.1053/j.gastro.2009.04.045] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 8.2] [Reference Citation Analysis]
19 Liang J, Ding T, Guo ZW, Yu XJ, Hu YZ, Zheng L, Xu J. Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. Br J Cancer. 2013;109:1031-1039. [PMID: 23868000 DOI: 10.1038/bjc.2013.390] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
20 Chen Y, Ayaru L, Mathew S, Morris E, Pereira SP, Behboudi S. Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma. PLoS One 2014;9:e88133. [PMID: 24520352 DOI: 10.1371/journal.pone.0088133] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
21 Sangro B, Palmer D, Melero I. Immunotherapy of hepatocellular carcinoma. Hepat Oncol 2014;1:433-46. [PMID: 30190978 DOI: 10.2217/hep.14.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
22 Behboudi S, Pereira SP. Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma. World J Hepatol 2010; 2(7): 256-260 [PMID: 21161007 DOI: 10.4254/wjh.v2.i7.256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
23 Kalathil SG, Thanavala Y. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. Cells 2021;10:1332. [PMID: 34071188 DOI: 10.3390/cells10061332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 He J, Zeng ZC, Fan J, Zhou J, Sun J, Chen B, Yang P, Wang BL, Zhang BH, Zhang JY. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation. BMC Cancer. 2011;11:492. [PMID: 22107882 DOI: 10.1186/1471-2407-11-492] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
25 Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. Journal of Hepatology 2011;54:830-4. [DOI: 10.1016/j.jhep.2010.10.013] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 6.0] [Reference Citation Analysis]
26 Wirth TC. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies. Expert Rev Gastroenterol Hepatol. 2014;8:101-110. [PMID: 24410473 DOI: 10.1586/17474124.2014.862497] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
27 Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:396. [PMID: 31500650 DOI: 10.1186/s13046-019-1396-4] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 25.3] [Reference Citation Analysis]
28 Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoim-munology. 2012;1:48-55. [PMID: 22720211 DOI: 10.4161/onc-i.1.1.18344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Schmidt N, Neumann-Haefelin C, Thimme R. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. Dig Dis. 2012;30:483-491. [PMID: 23108304 DOI: 10.1159/000341697] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
30 Terentiev AA, Moldogazieva NT. Alpha-fetoprotein: a renaissance. Tumour Biol. 2013;34:2075-2091. [PMID: 23765762 DOI: 10.1007/s13277-013-0904-y] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
31 Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med. 2014;12:86. [PMID: 24708667 DOI: 10.1186/1479-5876-12-86] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
32 Bogdanos DP, Gao B, Gershwin ME. Liver immunology. Compr Physiol. 2013;3:567-598. [PMID: 23720323 DOI: 10.1002/cphy.c120011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
33 Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med 2021;10:991. [PMID: 33801203 DOI: 10.3390/jcm10050991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Xu X, Xing B, Hu M, Xu Z, Xie Y, Dai G, Gu J, Wang Y, Zhang Z. Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for immunotherapy. Cytotherapy. 2010;12:190-200. [PMID: 19929456 DOI: 10.3109/14653240903390803] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
35 Schmidt N, Flecken T, Thimme R. Tumor-associated antigen specific CD8+ T cells in hepatocellular carcinoma - a promising target for immunotherapy. Oncoimmunology 2014;3:e954919. [PMID: 25941604 DOI: 10.4161/21624011.2014.954919] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
36 Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, Vogel A, Manns MP, Falk CS, Cornberg M, Wedemeyer H. HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver Cancer 2019;8:41-65. [PMID: 30815394 DOI: 10.1159/000490360] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
37 Morozov AV, Morozov VA, Astakhova TM, Timofeev AV, Karpov VL. DNA vaccine encoding α-fetoprotein fused with the ornithine decarboxylase degradation signal significantly suppresses the hepatocellular carcinoma growth in mice. Mol Biol 2012;46:391-406. [DOI: 10.1134/s0026893312030089] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Giraud J, Chalopin D, Blanc JF, Saleh M. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Front Immunol 2021;12:655697. [PMID: 33815418 DOI: 10.3389/fimmu.2021.655697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
39 Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693. [PMID: 25089265 DOI: 10.1155/2014/203693] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
40 Nakagawa H, Mizukoshi E, Kobayashi E, Tamai T, Hamana H, Ozawa T, Kishi H, Kitahara M, Yamashita T, Arai K, Terashima T, Iida N, Fushimi K, Muraguchi A, Kaneko S. Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma. Gastroenterology 2017;152:1395-1406.e10. [PMID: 28188748 DOI: 10.1053/j.gastro.2017.02.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
41 Sprinzl MF, Galle PR. Facing the dawn of immunotherapy for hepatocellular carcinoma. Journal of Hepatology 2013;59:9-10. [DOI: 10.1016/j.jhep.2013.04.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
42 Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology 2012;1:48-55. [PMID: 22720211 DOI: 10.4161/onci.1.1.18344] [Cited by in Crossref: 107] [Cited by in F6Publishing: 104] [Article Influence: 107.0] [Reference Citation Analysis]
43 Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62:1420-1429. [PMID: 25733155 DOI: 10.1016/j.jhep.2015.02.038] [Cited by in Crossref: 139] [Cited by in F6Publishing: 151] [Article Influence: 19.9] [Reference Citation Analysis]
44 Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, Gregory SH, Wands JR. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine 2015;33:1256-66. [PMID: 25629522 DOI: 10.1016/j.vaccine.2015.01.037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
45 Huang TM, Luo GR. Mechanisms underlying spontaneous regression of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2012; 20(21): 1939-1948 [DOI: 10.11569/wcjd.v20.i21.1939] [Reference Citation Analysis]
46 Aerts M, Benteyn D, Van Vlierberghe H, Thielemans K, Reynaert H. Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 253-261 [PMID: 26755874 DOI: 10.3748/wjg.v22.i1.253] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
47 Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Mukaida N, Matsushima K, Matsui O, Kaneko S. Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int J Cancer. 2010;126:2164-2174. [PMID: 19739081 DOI: 10.1002/ijc.24882] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
48 Mueller M, Spangenberg HC, Kersting N, Altay T, Blum HE, Klenerman P, Thimme R, Semmo N. Virus-specific CD4+ T cell responses in chronic HCV infection in blood and liver identified by antigen-specific upregulation of CD154. Journal of Hepatology 2010;52:800-11. [DOI: 10.1016/j.jhep.2009.12.038] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
49 Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Ueda T, Arihara F, Kagaya T, Yamashita T, Fushimi K, Kaneko S. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology. 2013;57:1448-1457. [PMID: 23174905 DOI: 10.1002/hep.26153] [Cited by in Crossref: 102] [Cited by in F6Publishing: 106] [Article Influence: 11.3] [Reference Citation Analysis]
50 Korangy F, Höchst B, Manns MP, Greten TF. Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2010;4:345-53. [PMID: 20528121 DOI: 10.1586/egh.10.18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]